Summary
Taxol (paclitaxel), an anti-microtubule agent extracted from the needles and bark of the Pacific yew treeTaxus brevifolia, has shown a remarkable anti-neoplastic effect in human cancer in phase I studies and early phase II and III trials thus far conducted. This has been reported primarily in advanced ovarian and breast cancer, although significant activity has also been documented in small-cell and non-small-cell lung cancer, head and neck cancers, and with lower activity in metastatic melanoma. The clinical utilization of Taxol had been previously somewhat restricted by its limited availability, a limitation that has recently been overcome by combined efforts of pharmaceutical, agricultural, and governmental agencies. In this review we shall address the pre-clinical data which have led to the use of Taxol in man, the main clinical results thus far obtained, the toxicities associated with its use, current ongoing trials and future clinical directions of this promising agent.
Similar content being viewed by others
References
Wani MC, Taylor HL, Wall ME, et al, Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia, J Am Chem Soc 93:2325, 1991
Rowinsky EK, Cavenave LA, Donehower RC, Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247, 1990
Schiff PB, Fant J, Horwitz SB, Promotion of microtubule assembly in vitro by Taxol. Nature 277:665, 1979
Kumar N, Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256:10435, 1981
Manfredi JJ, Horwitz SB, Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25:83, 1984
Rao S, Horwitz SB, Ringel I, Direct photoaffinity labeling of tubulin with Taxol. J Natl Cancer Inst 84:785, 1992
Parness J, Horwitz SB, Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479, 1981
Dustin P, Microtubules. Sci Am 243:66, 1980
Roberts JR, Rowinsky EK, Donehower RC, et al, Demonstration of the cell cycle positions for Taxol-induced “asters” and “bundles” by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of Taxolsensitive and resistant cells. J Histochem Cytochem 37:1659, 1989
Taxol clinical brochure. National Cancer Institute, Bethesda, 1983
Choy H, Rodriguez FF, Koester S, et al, Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774, 1993
Investigational Drug Branch, National Cancer Institute, Taxol (NSC 125973) clinical brochure. National Cancer Institute, Bethesda, 1990
Lorenz W, Reimann HJ, Schmal A, et al, Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions 7:63, 1977
Roth B, Yeap B, Wilding G, et al, Taxol (NSC 125973) in advanced, hormone-refractory prostate cancer: an ECOG phase II trial. Proc Am Soc Clin Oncol 11:196, 1992
Sarosy G, Kohn E, Stone DA, et al, Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165, 1992
Levin L, Hryniuk W, The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 5:756, 1987
McGuire WP, Rowinsky EK, Rosenhein NB, et al, Taxol: a unique antineoplastic agent with significant antitumor activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273, 1989
Einzig AI, Wiernik P, Sasloff J, et al, Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748, 1992
Thipgen T, Blessing J, Ball H, et al, Phase II trial of Taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9:604, 1990
Sarosy G, Kohn E, Link C, et al, Taxol dose intensification in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 11:226, 1992
Einzig AI, Gorowski E, Sasloff J, et al, Phase II trial of Taxol in patients with metastatic renal cell carcinoma. Cancer Invest 9:133, 1991
Holmes FA, Frye D, Theriault RS, et al, Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797, 1991
Reichman BS, Seidman AD. Crown JPA. et al, Taxol and recombinant granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol (in press)
Einzig AL, Wiernik PH, Lipsitz S, et al, Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). Proc Am Soc Clin Oncol 12:194, 1993
Forastiere AA, Neuberg D, Taylor IV SG, et al, Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. Proc. Am Soc Clin Oncol 12:277, 1993
Wilson WH, Berg S, Kang Y-K, et al, Phase I/II study of taxol 96-hour infusion in refractory lymphoma and breast cancer: pharmacodynamics and analysis of multidrug resistance (mdr-1). Proc Am Soc Clin Oncol 12:134, 1993
Einzig AI, Hochster HH, Wiernik PH, et al, Phase II trial of Taxol in patients with metastatic melanoma. Invest New Drugs 9:54, 1991
Legha SS, Ring S, Papadopoulos N, A phase II trial of Taxol in metastatic melanoma. Cancer 65:2478, 1990
Chang AY, Kim K, Glick J, et al, Phase II study of Taxol, Merbarone, and Piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388, 1993
Murphy WK, Fossella FV, Winn RJ, et al, Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384, 1993
Brown T, Tangen C, Fleming T, et al, A phase II trial of Taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 12:200, 1993
Ettinger DS, Finkelstein DM, Sarma R, et al, Phase II study of Taxol in patients with extensive-stage small cell lung cancer (SCLC): an Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 12:1095, 1993
Swenerton K, Eisenhauer E, Bokkel Huinink W ten, et al, Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion. Proc Am Soc Clin Oncol 12:256, 1993
Nabholtz JM, Gelmon K, Bontenbal M, et al, Randomized trial of two doses of Taxol in metastatic breast cancer: an interim analysis. Proc Am Soc Clin Oncol 12:60, 1993
Seidman AD, Crown JPA, Reichman BS, et al, Lack of clinical cross-resistance of Taxol with anthracycline in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 12:63, 1993
Seidman AD, McCarthy J, Anthony V, et al, Pain and quality of life assessment in patients receiving Taxol and recombinant human granulocyte colony stimulating factor for metastatic breast cancer. Proceedings of the 2nd National Cancer Institute Workshop on Taxol and Taxus September 23–24, 1992
Holmes FA, Valero V, Theriault RL, et al, Phase II trial of Taxol in metastatic breast cancer refractory to multiple prior treatments. Proc Am Soc Clin Oncol 12:94, 1993
Rowinsky EK, Gilbert MR, McGuire WP, et al, Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692, 1991
Forastiere AA, Rowinsky E, Chaudry V, et al, Phase I trial of Taxol (T) and cisplatin (C)+G-CSF in solid tumors. Proc Am Soc Clin Oncol 289:1992
Holmes FA, Frye D, Valero V, et al, Phase I study of Taxol (T) and doxorubicin (D) with G-CSF in patients without prior chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 11:60, 1992
Fisherman J, McCabe M, Hillig M, et al, Phase I study of Taxol and doxorubicin (DOX) with G-CSF in previously untreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 11:57, 1992
Pestalozzi BC, Sotos GA, Choyke PL, et al, Typhlitis resulting from treatment with Taxol and doxorubicin in patients with metastatic breast cancer. Cancer 71:1797, 1993
Kennedy MJ, Donchower RC, Sartorius SE, et al, Sequences of Taxol and cyclophosphamide: a phase I and pharmacologic study in doxorubicin resistant metastatic breast cancer. Proc Am Soc Clin Oncol 12:165, 1993
Kohn E, Reed E, Link C, et al, A pilot study of Taxol, cisplatin, cyclophosphamide, and G-CSF in newly diagnosed stage III/IV ovarian cancer patients. Proc Am Soc Clin Oncol 12:257, 1993
McGuire WP, Hoskins WJ, Brady MF, et al, A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC), Proc Am Soc Clin Oncol 12:255, 1993
Hudis C, Lebwohl D, Crown J, et al, Feasibility of dose-intensive cyclophosphamide with G-CSF after doxorubicin in women with high risk stage II/III resectable breast cancer. Proc Am Soc Clin Oncol 11:55, 1992
Weiss R, Donehower RC, Cates AE, et al, Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263, 1990
National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, National Cancer Institute, Bethesda, 1991
Peereboom DM, Donehower RC, Eisenhauer A, et al, Successful re-treatment with Taxol after major hypersensitivity reactions. J Clin Oncol 11:885, 1993
Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von-Hoff D, A phase I trial of Taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261, 1991
Roberts RL, Nath J, Friedman MM, Gallin JI, Effects of Taxol on human neutrophils. J Immunol 129:2134, 1982
Lipton RB, Apfel SC, Dutcher JP, et al, Taxol produces a predominantly sensory neuropathy. Neurology 39:368, 1989
Masurovsky EB, Peterson ER, Crain SM, et al, Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to Taxol. Neuroscience 10:491, 1983
Letourneau PC, Shattuck TA, Ressler AH, et al, Branching of sensory and sympathetic neurites in vitro is inhibited by treatment with Taxol. J Neurosci 6:1912, 1986
Rowinsky EK, McGuire WP, Guarnieri T, et al, Cardiac disturbances during the administration of Taxol. J Clin Oncol 9:1704, 1991
Rowinsky EK, Burke PJ, Karp JE, et al, Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 49:4640, 1989
Hruban RH, Yardley JH, Donehower RC, et al, Taxol toxicity: epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944, 1989
Markman MM, Rowinsky E, Hakes T, et al, Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol 9:1485, 1992
Francis P, Rowinsky E, Hakes T, et al, Phase I trial of weekly intraperitoneal (IP) Taxol in patients with residual ovarian carcinoma. Proc Am Soc Clin Oncol 12:257, 1993
Ringel I, Horwitz SB, Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288, 1991
Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F, Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845, 1991
Aapro M, Braakhuis B, Dietel M, et al, Superior activity of Taxotere (Ter) over Taxol (Tol) in vitro. Proc Am Assoc Cancer Res 33:516, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Foa, R., Norton, L. & Seidman, A.D. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 24, 6–14 (1994). https://doi.org/10.1007/BF02592403
Issue Date:
DOI: https://doi.org/10.1007/BF02592403